Overexpression of cyclooxygenase-2 (COX-2) and prostaglandins (PG) is linked to a wide variety of human cancers. Here, we assessed whether the chemotherapeutic effect of grape seed proanthocyanidins (GSP) on non-small cell lung cancer (NSCLC) cells is mediated through the inhibition of COX-2 and PGE 2 /PGE 2 receptor expression. The effects of GSPs on human NSCLC cell lines in terms of proliferation, apoptosis, and expression of COX-2, PGE 2 , and PGE 2 receptors were determined using Western blotting, fluorescence-activated cell sorting analysis, and reverse transcription-PCR. In vitro treatment of NSCLC cells (A549, H1299, H460, H226, and H157) with GSPs resulted in significant growth inhibition and induction of apoptosis, which were associated with the inhibitory effects of GSPs on the overexpression of COX-2, PGE 2 , and PGE 2 receptors (EP1 and EP4) in these cells. Treatment of cells with indomethacin, a pan-COX inhibitor, or transient transfection of cells with COX-2 small interfering RNA, also inhibited cell growth and induced cell death. The effects of a GSP-supplemented AIN76A control diet fed to nude mice bearing tumor xenografts on the expression of COX-2, PGE 2 , and PGE 2 receptors in the xenografts were also evaluated. The growth-inhibitory effect of dietary GSPs (0.5%, w/w) on the NSCLC xenograft tumors was associated with the inhibition of COX-2, PGE 2 , and PGE 2 receptors (EP1, EP3, and EP4) in tumors. This preclinical study provides evidence that the chemotherapeutic effect of GSPs on lung cancer cells in vitro and in vivo is mediated, at least in part, through the inhibition of COX-2 expression and subsequently the inhibition of PGE 2 and PGE 2 receptors.
Introduction
Lung cancer is the leading cause of cancer-related deaths in men and women in the United States and worldwide (1) . One of every three cancer-related deaths is attributable to lung cancer, and the dismal 5-year survival rate of ∼14% has shown no improvement over the past three decades (2, 3) . Although a combination of chemotherapy and radiation therapy can improve survival, most patients die of disease progression, which is often associated with acquired or intrinsic resistance to chemotherapeutic drugs (4-6). Cyclooxygenase-2 (COX-2) is frequently constitutively elevated in different human malignancies, including lung cancers (7-10 11) as well as colorectal (12, 13) , prostate (14) , and breast (15, 16) cancers. Although multiple genetic alterations are necessary for lung cancer development, COX-2 may be a central element in orchestrating this process. Overexpression of COX-2 promotes tumor cell resistance to apoptosis (17, 18) and increases angiogenesis and tumor invasion (19, 20) . Cyclooxygenases, which are the rate-limiting enzymes in prostanoid synthesis, convert arachidonic acid into prostaglandin (PG) H 2 , a substrate for specific PG synthases (21) . Two isoforms of COX, a constitutively expressed form, COX-1, and an inducible form, COX-2, have been identified. COX-2 inhibitors have been shown to inhibit tumor growth and metastasis in several animal models, including models of lung cancer (22) . The current treatment strategies for advanced lung cancer include surgical resection, radiation, cytotoxic chemotherapy, and photodynamic therapy (5) . In almost two thirds of cases, the cancer has already spread beyond localized disease at the time of diagnosis, limiting therapeutic options (23, 24) . Therefore, the exploration and development of more effective chemopreventive/chemotherapeutic agents and therapies that can target the molecules associated with tumor proliferation, angiogenesis, and apoptosis resistance will lead to improved outcomes in patients with lung cancer.
Phytochemicals, particularly those that can be administered as dietary supplements, offer promising new options for the development of more effective chemopreventive and chemotherapeutic strategies. Grape seed proanthocyanidins (GSP) have anticarcinogenic properties (25) and seem to exhibit minimal toxicity (26, 27) . GSPs are a mixture of polyphenols/flavanols and primarily contain proanthocyanidins (89%), which constitute dimers, trimers, tetramers, and oligomers/polymers of monomeric catechins and/or (−)-epicatechins (25, 27) . GSPs are readily available as an extract of grape seeds and this extract, rather than the individual constituents, is used in determining the chemotherapeutic effects of GSPs as it represents a feasible and affordable dietary phytochemical.
Recently, we found that dietary GSPs resulted in the significant inhibition of the growth of human non-small cell lung cancer (NSCLC) cell xenografts in nude mice and that this was associated with the inhibition of lung tumor cell proliferation and the inhibition of angiogenic factors (28) . In the present study, we investigated the mechanism responsible for the inhibition of lung cancer cell proliferation using in vitro and in vivo models. We report that treatment of NSCLC cells with GSPs induces apoptotic cell death, and this cell death is mediated through the inhibition of COX-2 expression and the associated inhibition of PGE 2 and PGE 2 receptors. Our results provide a convincing rationale for the pharmacologic activity of GSPs against NSCLC cells in in vitro and in vivo models.
Materials and Methods

Cell Culture and Cell Lines
The human NSCLC lines (A549, H1299, H226, H460, H1975, H1650, HCC827, and H157) were purchased from the American Type Culture Collection. Normal (nonmalignant) human bronchial epithelial cells (BEAS-2B) from the American Type Culture Collection were used as a control. The lung cancer cell lines were cultured as monolayers in Ham's F-12 or RPMI 1640 culture media supplemented with 10% heat-inactivated fetal bovine serum (Hyclone), 100 μg/mL penicillin, and 100 μg/mL streptomycin and maintained in an incubator with a humidified atmosphere of 95% air and 5% CO 2 at 37°C. The GSPs were dissolved in a small amount of DMSO before addition to the complete cell culture medium [maximum concentration of DMSO, 0.1% (v/v) in media] and addition of the media to subconfluent cells (60-70% confluent). Cells treated only with DMSO served as a control. To study the effect of PGE 2 , cells were treated with PGE 2 (10 μg/mL) for 10 min. For studies of the effects of inhibitors on PGE 2 treatment, the cells were pretreated with the respective inhibitors at the indicated concentrations 1 h before the addition of PGE 2 .
Antibodies, PCR Primers, and Chemicals
Antibodies specific for COX-2, an enzyme immunoassay kit for PGE 2 analysis, and an EP4 agonist (PGE1 alcohol) were obtained from Cayman Chemicals. The antibodies specific for EP1, EP2, EP3, and EP4 and their secondary antibodies were obtained from Cell Signaling Technology, Inc. The PCR primers of known sequences of EP1, EP2, EP3, and EP4 were obtained from Invitrogen.
The enhanced chemiluminescence detection reagents for Western blotting were purchased from Amersham Pharmacia Biotech.
Cell Proliferation Assay
The effect of GSPs on the proliferative capacity of the cells was determined using the MTT assay as previously described (28) . The effect of GSPs on cell viability was assessed as the percent cell viability compared with vehicle-treated control cells, which were arbitrarily assigned 100% viability.
Analysis of Apoptotic Cell Death by Flow Cytometry
GSP-induced apoptosis of the human NSCLC cells was determined by flow cytometry using the Annexin V-conjugated Alexa Fluor488 (Alexa488) Apoptosis Detection kit following the instructions of the manufacturer, and as described by us (28, 29) . Briefly, after overnight serum starvation, cells were treated with varying concentrations of GSPs for 48 h. The cells were then harvested, washed in PBS, and incubated with Alexa488 and propidium iodide in the dark at room temperature. The stained cells were analyzed by fluorescence-activated cell sorting using a FACSCalibur instrument (BD Biosciences) equipped with the CellQuest 3.3 software. The experiments were repeated twice.
Source and Administration of GSPs
We routinely receive GSPs for our research from Kikkoman Corporation, Japan. The GSPs preparation contains ∼89% proanthocyanidins, with dimers (6.6%), trimers (5.0%), tetramers (2.9%), and oligomers (74.8%) as described earlier (26, 27) . GSPs are stable for at least 2 y when refrigerated at 4°C. The experimental AIN76A control diet containing GSPs is prepared in pellet form by TestDiet for our research using the GSPs that we provide for this purpose.
Analysis of PGE 2 by Enzyme Immunoassay
Skin or tumor samples were homogenized in 100 mmol/L phosphate buffer (pH 7.4) containing 1 mmol/L ethylenediamine tetraacetic acid and 10 μmol/L indomethacin using a polytron homogenizer (PT3100, Fisher Scientific). The supernatants were collected after centrifugation and the concentration of PGE 2 was determined in supernatants using the Cayman PGE 2 Enzyme Immunoassay kit following the manufacturer's protocol.
Preparation of Cell or Tumor Xenograft Lysates and Western Blot Analysis
Following treatment of the NSCLC cells with or without GSPs, the cells were harvested, washed with cold PBS, and lysed with ice-cold lysis buffer supplemented with protease inhibitors, as detailed previously (28, 29) . Lysates of tumor xenografts were prepared similarly. For immunoblotting, the proteins were resolved on 10% Tris-glycine gels and transferred onto a nitrocellulose membrane. After blocking the nonspecific binding sites, the membrane was incubated with the primary antibody at 4°C overnight. The membrane was then incubated with the appropriate peroxidase-conjugated secondary antibody and the immunoreactive bands were visualized using enhanced chemiluminescence reagents. Each membrane was stripped and reprobed with anti-β-actin antibody to verify equal protein loading.
COX-2-Small Interfering RNA Transfection of A549 and H1299 Cells
Human-specific COX-2 small interfering RNA (siRNA) was transfected into A549 and H1299 cells using the siR-NA Transfection Reagent kit (Santa Cruz Biotechnology, Inc.) according to the manufacturer's protocol. Briefly, 2 × 10 5 cells per well were seeded in a six-well plate and allowed to grow to 70% confluency. The COX-2 siRNA mix with transfection reagents was overlaid on the cells for ∼6 h at 37°C and transferred into 2× growth medium for about 18 to 20 h. At 24 h posttransfection, fresh medium was added to the cells, and the cells incubated for an additional 48 h. Thereafter, cells were harvested and analyzed for cell death using a trypan blue exclusion assay. The knockdown of COX-2 expression in cells after transfection was confirmed using Western blot analysis.
Reverse Transcription-PCR for EP Receptors
RNA was isolated from NSCLC cell lines (A549 and H1299) treated with or without GSPs using the RNAEasy kit (Qiagen) and were reverse transcribed using the SuperScript II reverse transcriptase (Invitrogen). PCR was done using the Taq polymerase from New England Biolabs. The following primer pairs (F, forward; R, reverse primers 5′-3′; amplicon sizes are in parentheses) were used for EP receptor and β-actin amplification:
. PCR conditions were 5 min at 95°C followed by 35 cycles (25 for β-actin): 1 min at 95°C, 1 min at 58°C, and 1 min at 72°C, as reported (30) .
Animals and Tumor Xenograft Assay
Details of this experiment are previously described in ref. (28) . Briefly, the female athymic nude mice (6-to 7-wk-old) used in these studies were purchased from the National Cancer Institute. National Cancer Institute provided the sterilized AIN76A diet and water ad libitum. Mice in the experimental groups were given the AIN76A diet supplemented with GSPs (28) . To determine the in vivo efficacy of GSPs against human NSCLC tumor xenograft growth, exponentially growing A549 and H1299 cells were mixed at a 1:1 ratio with Matrigel (Becton Dickinson), and a 100 μL suspension containing 2 × 10 6 cells was injected s.c. in the right flank of each mouse (n = 10). At the termination of the experiment, the entire tumor mass was recovered and used for the analysis of biomarkers of interest.
Statistical Analysis
The results of the cell viability, cell death, and PGE 2 analyses were expressed as the mean ± SD. The statistical significance of difference between the values of control and treatment groups was determined using either two-tailed Student's t test or ANOVA followed by post hoc Tukey's test. A P value of <0.05 was considered statistically significant.
Results
GSPs Inhibit Proliferation of Human NSCLC Cells but not Normal Human Bronchial Epithelial Cells
We have reported previously that the treatment of NSCLC cells with GSPs inhibits their proliferation as determined using an MTT assay (28) . As shown in Fig. 1 , these results were confirmed using human NSCLC cell lines with different genetic characteristics, including p53 wild-type (A549), p53 mutated (H1299), and epidermal growth factor receptor positive (A549, H1299, H226, and H460). Treatment of these NSCLC cells with various concentrations of GSPs (0, 20, 40, 60, or 80 μg/mL) for 48 h resulted in a significant reduction in cell viability (10-68%, P < 0.05-0.001) as assessed using the MTT assay (Fig. 1A , left). It is evident from the data that different NSCLC cell lines differ in their sensitivity to GSPs and that the IC 50 for the GSPs is cell line dependent. We also examined the effects of GSPs on normal (nonneoplastic) human bronchial epithelial cells (BEAS-2B) under identical conditions. We did not find significant inhibition of cell proliferation of normal human bronchial epithelial cells after GSPs treatment at the concentrations of 20, 40, 60, or 80 μg/mL for 24, 48, or 72 hours (Fig. 1B) . Although an inhibitory effect of GSPs on normal bronchial epithelial cells was noted at the 96-hour time point, the inhibition was significantly lower than the effect of equivalent concentrations of GSPs on the NSCLC cells at the same time point (P < 0.001).
GSPs Induce Apoptotic Cell Death of Human NSCLC Cells
To determine whether the GSP-induced inhibition of cell proliferation or cell viability of the human lung cancer cells was associated with the induction of apoptosis, two representative cell lines, A549 and H1299, were treated with various concentrations of GSPs, and apoptosis was assessed using the Annexin V-conjugated Alexa Fluor 488 (Alexa488) Apoptotic Detection kit, as previously described (29) . As shown in Fig. 1C , apoptotic cells were counted as "late" or "early" apoptotic cells, which are shown, respectively, in the upper-right (UR) and lower-right (LR) quadrants of the histograms presented in Fig. 1C . GSP treatment of A549 cells for 48 hours resulted in a highly significant dose-dependent enhancement in the numbers of cells in the early and late stages of apoptosis ( Fig. 1C, left) : 0 μg/mL (vehicle control, 6.3%), 20 μg/mL (18.6%, P < 0.05), 40 μg/mL (32%, P < 0.01) and 80 μg/mL (49.3%, P < 0.001; summarized in Fig.  1D ). Similar results were obtained on GSP treatment of A549 cells for 72 hours except that the percentages of apoptotic cells were slightly higher than 48 hours (data not shown). Treatment of H1299 cells with GSPs at the various concentrations of GSPs also resulted in a significant Figure 1 . In vitro treatment of human NSCLCs with GSPs inhibits the proliferation potential and induces apoptosis in a dose-dependent manner. A, comparative dose-dependent effect of GSPs on the proliferation potential of human NSCLC cells, A549, H1299, H226, H460, and H157, 48 h after treatment (29) . B, the concentration-and time-dependent effect of GSPs on the proliferation potential of normal human bronchial epithelial cells (BEAS-2B). Cell viability was determined using the MTT assay as described in Materials and Methods and is expressed in terms of percent of vehicle-treated (0.2% DMSO) control cells; points, mean of eight replicates; bars, SD. C and D, GSPs induce apoptosis in A549 and H1299 cells. Apoptotic cell death was analyzed as detailed in Materials and Methods. C, the lower-right (LR) quadrant of the fluorescence-activated cell sorting histograms indicates the percentage of early apoptotic cells, and the upper-right (UR) quadrant indicates the percentage of late apoptotic cells. D, total percentages of apoptotic cells in A549 and H1299 are summarized; columns, mean from three experiments; bars, SEM. Significant difference versus non-GSP-treated controls: *, P < 0.05; ¶, P < 0.01; †, P < 0.001. Figure 2 . GSPs inhibit the basal levels of COX-2 and PGE 2 expression in NSCLC cells. A and B, the basal constitutive expression levels of COX-2 and PGE 2 in seven different NSCLC cell lines and normal human bronchial epithelial cells were determined by (A) Western blot analysis of cell lysates to estimate the basal levels of COX-2 and (B) an enzyme-linked immunoassay of PGE 2 in samples of cell homogenates. C, treatment of H1299, A549, and H460 cells with GSPs inhibits the basal levels of COX-2 expression dose dependently. Cells were treated with the various concentrations of GSPs for 48 h, then harvested, and cell lysates were subjected to Western blot analysis. D, the amount of PGE 2 was determined in the cell homogenates from the same experiment as detailed in C using an enzyme immunoassay. The concentration of PGE 2 is expressed in terms of pg/mg protein; columns, mean of three independent experiments; bars, SD. Significant inhibition versus non-GSP-treated controls: *, P < 0.05; ¶, P < 0.01; †, P < 0.001.
dose-dependent induction of apoptosis at 48 hours: 0 μg/mL (vehicle control, 3.7 ± 1%), 20 μg/mL (17 ± 2%, P < 0.05), 40 μg/mL (33.2 ± 2%, P < 0.01), and 80 μg/mL (51 ± 3%, P < 0.001; Fig. 1C and D, right) . These results provide evidence that human NSCLC cells are sensitive to GSP-induced apoptosis. Treatment of normal human bronchial epithelial cells with GSPs for 48 hours did not result in the significant enhancement of apoptosis of these cells (data not shown). Although a slightly higher number of apoptotic cells was observed on treatment of normal bronchial epithelial cells with 80 μg/mL GSPs for 48 hours, this did not reach significance and was significantly less (P < 0.001) than the levels of apoptosis of A549 or H1299 cells induced by treatment with the same concentration of GSPs at the same time point.
Human NSCLC Cells Overexpress COX-2 and Exhibit Enhanced PGE 2 Production
We were interested in determining whether higher levels of COX-2 contribute to the proliferation of lung cancer cells. The levels of COX-2 in lung cancer cells were compared with the levels in normal human bronchial cells. For this purpose, the levels of expression of COX-2 were assessed in cell lysates of various NSCLC cell lines, A549, H1299, H460, H226, H1975, H1650 and HCC827, and BEAS-2B cells, by Western blot analysis. As shown in Fig. 2A , the levels of COX-2 expression were higher in the NSCLC cells than in the normal human bronchial epithelial cells. Among the lung cancer cell lines tested, the A549, H1299, and H460 cell lines expressed higher levels of COX-2. We also determined the levels of PGE 2 production in the same cell lines cultured using an identical protocol. Homogenates of equal numbers of cells were analyzed for PGE 2 production. As shown in Fig. 2B , the levels of PGE 2 were higher in the NSCLC cell lines than the normal human bronchial epithelial cells. As had been observed for the levels of COX-2, the concentrations of PGE 2 were higher in the A549, H1299, and H460 cell lines than the other human lung cancer cell lines tested.
GSPs Reduce the Constitutive Overexpression of COX-2 and PGE 2 Production in NSCLC Cell Lines
To examine whether GSPs have any effect on the constitutive level of COX-2 in human lung cancer cell lines, we treated the A549, H1299, and 460 cell lines, which have higher levels of COX-2 expression than the other cell lines, with various concentrations of GSPs (0, 20, 40, 60, or 80 μg/mL) for 24 hours. The levels of COX-2 expression in the lysates of the cells was then determined using Western blot analysis. The data revealed that the treatment of lung cancer cells with GSPs resulted in a dose-dependent inhibition of COX-2 expression in all the human NSCLC cell lines tested (Fig. 2C) .
As increased expression of COX-2 results in the formation of greater amounts of PG metabolites, we also determined the levels of PG metabolites in these cells with a particular emphasis on PGE 2 because PGE 2 plays a pivotal role in inflammation-associated diseases, including lung cancer. We found that the treatment of A549, H1299, and H460 cell lines with GSPs for 24 hours resulted in a dose-dependent inhibition of PGE 2 production (P < 0.05-0.001) compared with cells which were not treated with GSPs (Fig. 2D) .
Treatment of NSCLC Cells with Indomethacin, a Pan-Inhibitor of COX, Inhibits Cell Growth and Increases Cell Death
As we found that the treatment of the various NSCLC cell lines used in this study with GSPs resulted in the inhibition of cell growth/proliferation, and inhibition of cell proliferation is associated with a reduction in the levels of COX-2 expression and PGE 2 production, we further sought to determine the effects of indomethacin, a well-known COX inhibitor, on these NSCLC cells. This experiment was done to determine whether the inhibitory effect of GSPs on NSCLC cell growth/proliferation is mediated through its inhibitory effect on COX-2 expression. For this purpose, equal numbers of A549, H1299, H460, and H226 cells were plated in tissue culture plates and treated with various concentrations of indomethacin (0, 20, 40, or 60 μmol/L) for 48 hours. Cell growth and morphology was checked microscopically, and cell viability and cell death were determined using MTT and trypan blue exclusion assays, respectively. As shown in Fig. 3A and B, treatment of the cells with indomethacin resulted in a dose-dependent reduction in the growth of the cells and cell viability compared with nonindomethacin-treated controls (P < 0.01-0.001). The results of the trypan blue exclusion assay revealed that the percentage of dead cells was significantly increased (P < 0.05-0.001) with the increasing doses of indomethacin (Fig. 3C) . As overexpression of COX-2 is primarily responsible for rapid cancer cell proliferation and growth, these data suggested that the inhibition of constitutive levels of COX including COX-2 expression in the presence of indomethacin resulted in the induction of NSCLC cell death and inhibition of NSCLC cell proliferation. A, phase-contrast microscopy examination suggests the inhibition of cellular proliferation and induction of cell death. The presence of micronuclei indicates cell death. B, cell viability was determined by counting the total number of cells using a hemocytometer; C, cell death was analyzed using a trypan blue assay. The experiment was repeated twice. Cell death and/or cell viability was determined at least thrice using a sample from each individual experiment. Significant difference versus nonindomethacin-treated control cells: *, P < 0.05; †, P < 0.001. D, transfection of cells with COX-2 siRNA increases cell death. Cells were transfected with COX-2 siRNA to knock down COX-2 expression. Representative photomicrographs are shown from two independent experiments. Percent cell death was determined using trypan blue exclusion assay, and data are expressed in terms of percent cell death; columns, mean; bars, SD. Significant difference versus control siRNA-treated cells: †, P < 0.001.
Knockdown of COX-2 Leads to the Inhibition of Cell Growth and an the Increase in Cell Death in NSCLC Cells
It has been shown that the overexpression of COX-2 contributes to cell survival and antiapoptotic effects in cancer cells. We therefore examined whether siRNA knockdown of COX-2 in the lung cancer cells would lead to the inhibition of the growth and induction of cell death of NSCLC cells. The transfection of A549 and H1299 cells with COX-2 siRNA resulted in marked reduction of cell growth and induction of cell death (64-68%, P < 0.001) after 48 hours of transfection compared with control siRNA-transfected A549 and H1299 cells (Fig. 3D) .
GSPs Inhibit PGE 2 -Induced Cell Proliferation of NSCLC Cells
Next, we determined the effect of PGE 2 on NSCLC cells and examined whether GSPs inhibit PGE 2 -induced cell proliferation in human lung cancer cells. For this purpose, A549 and H1299 cells were treated with PGE 2 (10 μmol/L) with and without the treatment of GSPs for 48 hours. The cells were then harvested and cell proliferation was estimated using the MTT assay. We found that the treatment of lung cancer cells with PGE 2 for 48 hours resulted in a significant increase in proliferation as indicated by the enhanced absorbance at 540 nm compared with the cells that were not treated with PGE 2 (Fig. 4A) . Pretreatment of A549 and H1299 cells with various concentrations of GSPs (20, 40 , or 60 μg/mL) for 48 hours resulted in a dose-dependent inhibition of this PGE 2 -induced cell proliferation (Fig. 4A) . We also examined the effect of GSPs on the proliferation of NSCLC cells that were treated with PGE 2 (10 μmol/L) or indomethacin (40 μmol/L) alone or in combination. As shown in Fig. 4B , PGE 2 treatment enhanced the proliferation of both A549 and H1299 cells compared with non-PGE 2 -treated cells. In contrast, indomethacin treatment significantly inhibited (P < 0.01) the proliferation of both cell lines compared with nonindomethacin-treated control cells, as well as PGE 2 -stimulated cell proliferation (P < 0.05). Under similar conditions, the combined treatment of cells with GSPs + indomethacin synergistically decreased (P < 0.01-0.001) PGE 2 -stimulated cellular proliferation of both A549 and H1299 cells.
GSPs Block the Upregulation of PGE 2 Receptors in Lung Cancer Cells
It is known that PGE 2 manifests its biological activity via four known G protein-coupled receptors (i.e., EP1-EP4; ref. 31) . Therefore, we determined the effect of GSPs on PGE 2 receptors. Analysis of A549 and H1299 cells treated with concentrations of GSPs (0, 10, 20, 40, or 60 μg/mL) for 48 hours by reverse transcription-PCR indicated a dose-dependent decrease in the levels of EP1 and EP4 transcripts (Fig. 5A) . The inhibitory effect of GSPs on EP1 was less prominent than EP4. We did not detect any significant changes in the levels of EP2 or EP3 transcripts after GSP treatment of the cells. These results were further verified by Western blot analysis. As shown in Fig. 5B , the levels of EP1 and EP4 were reduced in a dose-dependent manner on treatment with GSPs.
An EP4 Agonist Enhances the Proliferation of Lung Cancer Cells and GSPs Inhibit the EP4 AgonistInduced Cellular Proliferation of Cells
To further examine the role of PGE 2 receptor (e.g., EP4) on the proliferation of NSCLC cells and the therapeutic effect of GSPs, A549 and H1299 cells were treated with an EP4 agonist (PGE1 alcohol) for 24 hours with or without the addition of GSPs. As shown in Fig. 5C , treatment of A549 and H1299 cells with the EP4 agonist resulted in the significant enhancement of cellular proliferation (P < 0.01). Treatment of cells with various concentrations of GSPs significantly inhibited (P < 0.01-0.001) EP4 agonist-induced proliferation in a dose-dependent manner. These data suggest that the stimulation of PGE 2 receptor in lung cancer cells has a role in cell proliferation, and that GSPs inhibit the NSCLC cell proliferation, at least in part, by inhibiting the levels of PGE 2 receptor. (20, 40 , or 60 μg/mL) before the addition of PGE 2 (10 μmol/L) for 48 h. Cells were harvested and proliferation was determined using the MTT assay. B, A549 and H1299 cells were treated with PGE 2 (10 μmol/L), indomethacin (40 μmol/L), or various concentrations of GSPs. Cells were pretreated with GSPs or indomethacin 1 h before the addition of PGE 2 . Cell proliferation was assessed after 48 h using the MTT assay. Cell viability is expressed as mean of color density; columns, mean absorbance at 540 nm from three independent experiments; bars, SD. Significant difference versus untreated control: **, P < 0.01; Significant difference versus PGE 2 alone-treated group: *, P < 0.05; ¶, P < 0.01; †, P < 0.001.
Effect of Dietary GSPs on the Levels of COX-2, PGE 2 , and PGE 2 Receptors on Lung Tumor Xenografts in Athymic Nude Mice
We have shown earlier that dietary GSPs inhibit the growth of A549 and H1299 NSCLC cells grown as xenografts in athymic nude mice (28) . The inhibitory effect of dietary GSPs on the growth of tumor xenografts are shown in Fig. 6A (28) . To examine the effect of dietary GSPs in vivo on the levels of COX-2, PGE 2 , and the receptors of PGE 2 , we used tumor xenograft samples from our previous experiment (28) . As the dietary GSPs at the concentration of 0.5% (w/w) supplemented with AIN76A control diet resulted in a significant inhibitory effect on tumor xenograft growth, we compared the data obtained from the analysis of lysates of A549 and H1299 tumor xenografts obtained from mice fed the control diet without GSPs (group 1) and mice fed the control diet supplemented with GSPs (0.5%; group 2). Western blot analysis revealed that the levels of COX-2 were lower in the tumor xenograft samples of A549 and H1299 cells in mice that were fed the diet supplemented with GSPs than in tumor xenografts from those mice that were not given GSPs in the diet (Fig. 6B) . The levels of PGE 2 were also significantly lowered (P < 0.001) in the tumor xenograft samples of A549 (62%) and H1299 (50%) cells in mice that were fed the diet supplemented with GSPs. Similarly, the levels of the PGE 2 receptors EP1, EP3, and EP4 were lower in the tumor xenografts from mice that were fed the GSPsupplemented diet than in the tumor xenografts from control mice that were not given dietary GSPs (Fig. 6B) .
Discussion
COX-2 is frequently overexpressed in a variety of human malignancies and is linked to all stages of tumorigenesis. Elevated tumor COX-2 expression is associated with Figure 5 . Treatment of A549 and H1299 cells with various concentrations of GSPs (0, 10, 20, 40, or 60 μg/mL) for 48 h inhibits the expression levels of PGE 2 receptors EP1 and EP4. A, the cells were harvested, RNA was isolated, and the levels of EP receptors were determined by reverse transcription-PCR, as detailed in Materials and Methods. β-Actin was used as an internal control. B, cell lysates were subjected to Western blot analysis to determine the levels of EP1 and EP4 receptors using EP1-and EP4-specific antibodies. Representative blots are shown from three independent experiments. C, GSPs inhibit EP4 agonist-induced (25 μmol/L) cell proliferation of A549 and H1299 cells. A549 and H1299 cells were treated with GSPs (20, 40, or 60 μg/mL) for at least 1 h before the addition of the EP4 agonist. Cell proliferation was assessed using the MTT assay 24 h after the GSP treatment; columns, mean absorbance at 540 nm from three independent experiments; bars, SD. Significant difference versus EP4 agonist alone-treated group: ¶, P < 0.01; †, P < 0.001.
increased angiogenesis, tumor invasion, and suppression of host immunity and promotes tumor cell resistance to apoptosis (31) . Because of its important role in tumor progression, COX-2 is a promising target for cancer therapy (31) . Although multiple genetic alterations are necessary for lung cancer development, COX-2 enzymatic products may be central to orchestrating this process. Most of the protumorigenic effects of COX-2 have been attributed to its metabolic product, PGE 2 , an important mediator of tumor growth. A high concentration of PGE 2 due to COX-2 overexpression in neoplastic cells shifts the balance of these tumorigenic processes, creating a permissive microenvironment for tumor growth. Therefore, the search of potential COX-2 inhibitors for the prevention or treatment of lung cancer may prove to be an important strategy. Phytochemicals offer promising options for more effective treatment strategies for lung cancer. GSPs represent one such phytochemical agent that has been shown to have anticarcinogenic activity (25) , including activity against lung cancer cells (28). As we had found that Figure 6 . A, dietary GSPs inhibit the growth of A549 and H1299 NSCLC cells grown as xenografts in athymic nude mice (29) . Tumor xenograft tissues were harvested at the termination of the experiment; columns, mean wet weight of the tumor/mouse in each group is reported in grams (n = 10); bars, SD. Statistical significance versus non-GSPstreated controls: *, P < 0.05; ¶, P < 0.01; †, P < 0.001. B, tumor xenograft tissues from control and GSP-treated (0.5%, w/w) mice were used for the analysis of the levels of COX-2 and PGE 2 receptors using Western blotting. Dietary GSPs inhibit the levels of COX-2 and PGE 2 receptors, EP1, EP3, and EP4, in the tumor xenograft tissues grown in athymic nude mice compared with control tumor xenograft tissues. Representative blots from A549 or H1299 xenografts are presented from the independent analysis of tumors from six animals per group with identical results. The relative density (arbitrary) of each band after normalization for β-actin is shown under each immunoblot as the fold change compared with non-GSP-treated control, which was assigned an arbitrary unit 1 in each case. PGE 2 was determined in tumor xenograft tissue samples using a PGE 2 immunoassay kit following the manufacturer's instructions. The concentration of PGE 2 is expressed in terms of pg/mg protein; columns, mean (n = 10); bars, SD. Significantly lower versus non-GSP-treated controls: †, P < 0.001.
dietary GSPs do not induce apparent toxicity in experimental animals, and inhibit cell proliferation of NSCLC cells in vitro and tumor xenograft growth in vivo in athymic nude mice, we conducted further studies to understand the molecular mechanisms involved in the GSPmediated inhibition of NSCLC cell growth in vitro and in vivo. The significant findings in the present study are that the treatment of NSCLC cells with GSPs induces apoptotic cell death, and that is associated with the inhibition of COX-2 expression and PGE 2 production. The NSCLC cells overexpress COX-2, and the inhibition of COX-2 by GSPs may have contributed to the apoptosis of these cells. This concept is supported by the evidence that the treatment of the NSCLC cells with indomethacin, a potent pan-COX inhibitor, resulted in a reduction in cell proliferation/cell viability and induction of cell death. Similar effects were also noted when lung cancer cells, A549 and H1299, were transfected with COX-2 siRNA. It has been reported that COX-2 inhibitors can induce apoptosis of NSCLC cells (13, 31) ; however, although certain COX-2 inhibitors primarily induce apoptosis, others may predominantly induce growth arrest (32) . It is well known that PGE 2 exerts its multiple actions through four G protein-coupled receptors, EP1, EP2, EP3, and EP4 (31) that can stimulate epithelial cell growth and invasion and promote cellular survival (17, 19) . Because PGE 2 is the major PG found in lung cancer cells (31), we focused on the possible involvement of the PGE 2 receptors in GSP-induced inhibition of NSCLC cell proliferation. We observed that A549 and H1299 cells express the PGE 2 receptors, EP1 and EP4, and that the expression of EP1 and EP4 was reduced when cells were treated with GSPs in vitro. These data suggest that the inhibition of the EP1 and EP4 levels by GSPs may contribute to the inhibition of tumor cell growth and induction of apoptosis of lung cancer cells. This assumption is based on the findings that PGE 2 receptors coupled to the GαS, and ligand binding has been reported to increase cyclic AMP levels leading to the activation of PKA and Akt (33) . Akt and PKA activation can mediate prosurvival pathways through the inactivation of proapoptotic proteins (34, 35) . Our results are consistent with the report that PGE 2 protected gastric mucosal cells in vitro from ethanol-induced apoptosis via EP1 and EP4 activation (36) . The inhibitory effect of GSPs on lung cancer cell proliferation through the inhibitory effect on EP1 or EP4 was further confirmed by treating the cells with EP4 agonist. We found that the treatment of A549 and H1299 cells with EP4 agonist (PGE1 alcohol) resulted in enhanced cell proliferation, and that EP4 agonist-induced cell proliferation was inhibited by the treatment of cells with GSPs. This observation further supports the concept that the inhibition of PGE 2 receptors by GSPs may have contributed to the inhibition of proliferation and induction of apoptosis in lung cancer cells.
To verify that GSPs can inhibit the growth of lung cancer cells in vivo through these mechanisms, lung tumor xenografts grown in athymic mice were analyzed for the expression of COX-2, PGE 2 , and PGE 2 receptors. A significant finding of the present study was the inhibition of tumor xenograft growth in athymic nude mice fed a diet supplemented with GSPs (0.5%, w/w) was associated with the inhibition of COX-2 and PGE 2 expression and a reduction in the levels of PGE 2 receptors, EP1, EP3, and EP4. These data suggest that the protective effects of the dietary GSPs on the growth of NSCLC cells in vivo are also mediated through the inhibition of PGE 2 and PGE 2 receptors.
It is also important to consider whether the effect of any chemopreventive agent in an animal model can be translated in human system. For appropriate conversion of chemopreventive/chemotherapeutic agent doses from animal studies to humans, the body surface area normalization method has been recommended (37) . In this study, we measured that each mouse (mean weight, 20 g) consumed ∼13.5 mg GSPs per day. Based on this information, the human equivalent dose of GSPs was calculated using the following formula:
Human equivalent dose ðmg=kgÞ ¼ Animal doseðmg=kgÞ Â Animal K m factor Human K m factor (K m factor for mouse = 3; K m factor for adult human = 37). If, the normal body weight of a person is considered to be 70 kg, then 3.8 g GSPs will be required for a person per day to produce same level of antilung carcinogenic effects as observed in mice, which seems reasonable, affordable, and attainable.
In summary, the results from this study show for the first time the chemotherapeutic efficacy of GSPs in controlling the proliferation and induction of apoptosis of human NSCLC cells in vitro and tumor xenograft growth in vivo through the inhibition of COX-2 and PGE 2 expression, and the role of PGE 2 receptors in this process. As the overexpression of COX-2 and subsequently overproduction of PGE 2 metabolite play a prominent role in lung cancer risk, the novelty of this study lies in the exploration of a new and more effective chemotherapeutic agent, and that is GSPs. More mechanism-based studies are therefore needed to develop GSPs as a pharmacologic safe agent for the prevention or treatment of lung cancer in humans.
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